Ajax Health Establishes Cortex, a Comprehensive AFib Ablation Technology Company, with $90 Million Investment Led by KKR and Hellman & Friedman
MENLO PARK, Calif., Dec. 7, 2023 /PRNewswire/ -- Ajax Health announced today the formation and funding of Cortex, a medical technology company developing an integrated mapping and ablation solution suite for the treatment of atrial fibrillation (AFib), the most common heart rhythm disorder, affecting more than 30 million patients worldwide. Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.
- Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.
- Cortex brings together expert teams with complementary innovations in electrophysiology to accelerate the continued development and clinical validation of next-generation ablation solutions and differentiated AFib mapping technology.
- "Cortex's vision is to enable more intelligent AFib treatment," said Duke Rohlen, CEO of Ajax Health and CEO of Cortex.
- EGF mapping allows physicians to detect AFib sources and is designed to support personalized ablation therapy to potentially improve outcomes.